Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP2741)
Name
Epsilon-viniferin
Synonyms
Epsilon-viniferin; 62218-08-0; epsilon-?Viniferin; CHEBI:10556; trans-epsilon-Viniferin; UNII-0K8Z2K6Y7O; 0K8Z2K6Y7O; CHEMBL1224875; C28H22O6; W2075; epsilon-viniferine; 5-[(2R,3R)-2,3-dihydro-6-hydroxy-2-(4-hydroxyphenyl)-4-[(1E)-2-(4-hydroxyphenyl)ethenyl]-3-benzofuranyl]-1,3-benzenediol; 5-[(2R,3R)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl]benzene-1,3-diol; AC1NQYZ4; Resveratrol dimer; 5-{(2R,3R)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl}benzene-1,3-diol; (-)-epsilon-Viniferin; (-)-trans- -viniferin; SureCN3041632; (-)-Trans-epsilon-viniferin; SCHEMBL3041632; epsilon-Viniferin , HPLC Grade; 253435-07-3; HY-N3841; ZINC4098643; BDBM50531887; MFCD12964987; 5-(2,3-Dihydro-6-hydroxy-2(4-hydroxyphenyl)4-(2-(4-hydroxyphenyl)ethenyl)-3-benzofuranyl)-1,3-benzenediol; CS-0024314; C10289; Q5383943; (2R)-2beta-(4-Hydroxyphenyl)-3alpha-(3,5-dihydroxyphenyl)-4-(4-hydroxystyryl)-2,3-dihydrobenzofuran-6-ol; 1,3-Benzenediol, 5-(2,3-dihydro-6-hydroxy-2(4-hydroxyphenyl)4-(2-(4-hydroxyphenyl)ethenyl)-3-benzofuranyl)-; 5-[(2R,3R)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)vinyl]-2,3-dihydrobenzofuran-3-yl]benzene-1,3-diol
    Click to Show/Hide
Species Origin Vitis vinifera ...     Click to Show/Hide
Vitis vinifera
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Vitales
Family: Vitaceae
Genus: Vitis
Species: Vitis vinifera
Disease Prediabete [ICD-11: 5A40] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C28H22O6
PubChem CID
5281728
Canonical SMILES
C1=CC(=CC=C1C=CC2=C3C(C(OC3=CC(=C2)O)C4=CC=C(C=C4)O)C5=CC(=CC(=C5)O)O)O
InChI
1S/C28H22O6/c29-20-7-2-16(3-8-20)1-4-18-11-24(33)15-25-26(18)27(19-12-22(31)14-23(32)13-19)28(34-25)17-5-9-21(30)10-6-17/h1-15,27-33H/b4-1+/t27-,28+/m1/s1
InChIKey
FQWLMRXWKZGLFI-YVYUXZJTSA-N
CAS Number
CAS 62218-08-0
ChEBI ID
CHEBI:10556
Herb ID
HBIN025468
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression CASP3  Molecule Info 
Pathway MAP
Up-regulation Expression CASP8  Molecule Info 
Pathway MAP
Up-regulation Expression CASP9  Molecule Info 
Pathway MAP
                    In-vitro Model C6 CVCL_0194 Rat malignant glioma Rattus norvegicus
                    Experimental
                    Result(s)
Caspase-8, -9, -3 activation which was determined in vitro, trigerred apoptotic mechanism in C6 cells by using low concentrations of combined cis-platin and Epsilon-viniferin.
References
Reference 1 Epsilon-Viniferin, a promising natural oligostilbene, ameliorates hyperglycemia and hyperlipidemia by activating AMPK in vivo. Food Funct. 2020 Nov 18;11(11):10084-10093.
Reference 2 Apoptotic effects of Epsilon-viniferin in combination with cis-platin in C6 cells. Cytotechnology. 2018 Jun;70(3):1061-1073.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China